We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU
Read MoreHide Full Article
PTC Therapeutics, Inc. (PTCT - Free Report) announced that both the FDA and the European Commission (EC) have granted an Orphan Drug designation to its pipeline candidate PTC923 which is being developed for the treatment of patients with hyperphenylalaninemia.
The company plans to begin a placebo-controlled phase III registrational study – APHENITY – in mid-2021, evaluating PTC923 for addressing patients with phenylketonuria (“PKU”), which accounts for 98% of all hyperphenylalaninemia cases.
Notably, the Orphan Drug designation is granted to drugs that are capable of treating rare diseases which affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses, an exemption from the FDA user fee and seven-year marketing exclusivity upon potential approval.
Also, the European Medicines Agency usually grants Orphan Medicinal Product status to drugs that target serious or life-threatening conditions in the region. Additionally, every indication will enjoy a period of 10 years of market exclusivity in the EU, if approved.
Shares of PTC Therapeutics have plunged 34.7% so far this year compared with the industry’s decrease of 11.3%.
Per the company, PKU is a metabolic condition which can lead to cognitive dysfunction, behavioral problems, seizures and psychiatric disorders. Hence, if successfully developed and upon potential approval, PTC923 can serve an area of high unmet medical need.
We remind investors that Swiss pharma giant Roche (RHHBY - Free Report) is developing Evrysdi (risdiplam) in collaboration with the SMA Foundation and PTC Therapeutics. The drug is approved for the treatment of spinal muscular atrophy (“SMA”) in the United States as well as in Europe.
PTC Therapeutics receives milestone payments from Roche from the sale of Evrysdi in the United States.
SMA is a severe, progressive neuromuscular disease that causes muscle weakness and progressive loss of movement, affecting one in 10,000 babies, and is the leading genetic cause of infant mortality.
However, competition is stiff in the SMA market from the likes of Biogen’s (BIIB - Free Report) Spinraza and Novartis’ (NVS - Free Report) gene therapy, Zolgensma.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency have sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU
PTC Therapeutics, Inc. (PTCT - Free Report) announced that both the FDA and the European Commission (EC) have granted an Orphan Drug designation to its pipeline candidate PTC923 which is being developed for the treatment of patients with hyperphenylalaninemia.
The company plans to begin a placebo-controlled phase III registrational study – APHENITY – in mid-2021, evaluating PTC923 for addressing patients with phenylketonuria (“PKU”), which accounts for 98% of all hyperphenylalaninemia cases.
Notably, the Orphan Drug designation is granted to drugs that are capable of treating rare diseases which affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses, an exemption from the FDA user fee and seven-year marketing exclusivity upon potential approval.
Also, the European Medicines Agency usually grants Orphan Medicinal Product status to drugs that target serious or life-threatening conditions in the region. Additionally, every indication will enjoy a period of 10 years of market exclusivity in the EU, if approved.
Shares of PTC Therapeutics have plunged 34.7% so far this year compared with the industry’s decrease of 11.3%.
Per the company, PKU is a metabolic condition which can lead to cognitive dysfunction, behavioral problems, seizures and psychiatric disorders. Hence, if successfully developed and upon potential approval, PTC923 can serve an area of high unmet medical need.
We remind investors that Swiss pharma giant Roche (RHHBY - Free Report) is developing Evrysdi (risdiplam) in collaboration with the SMA Foundation and PTC Therapeutics. The drug is approved for the treatment of spinal muscular atrophy (“SMA”) in the United States as well as in Europe.
PTC Therapeutics receives milestone payments from Roche from the sale of Evrysdi in the United States.
SMA is a severe, progressive neuromuscular disease that causes muscle weakness and progressive loss of movement, affecting one in 10,000 babies, and is the leading genetic cause of infant mortality.
However, competition is stiff in the SMA market from the likes of Biogen’s (BIIB - Free Report) Spinraza and Novartis’ (NVS - Free Report) gene therapy, Zolgensma.
Zacks Rank
PTC Therapeutics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency have sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>